Keywords

Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction to catalytic events.

PDUFA Dates

The FDA is scheduled to give its verdict on Roche Holdings AG Basel ADR's (OTC: RHHBY) Tecentriq in combination with Bristol-Myers Squibb Co's (NYSE: BMY) chemo medications Carboplatin and Abraxane in patients with metastatic non-squamous NSCLC, who do not have EGFR or ALK genomic tumor aberrations. The PDUFA action date is fixed for Monday.